Striatal Glutamate, Subcortical Structure and Clinical Response to First-line Treatment in First-episode Psychosis Patients
Overview
Authors
Affiliations
Introduction: Recent studies have observed that patients with treatment-resistant schizophrenia as well as patients with schizophrenia who do not respond within a medication trial exhibit excess activity of the glutamate system. In this study we sought to replicate the within-trial glutamate abnormality and to investigate the potential for structural differences and treatment-induced changes to improve identification of medication responders and non-responders.
Methods: We enrolled 48 medication-naïve patients in a 4-week trial of risperidone and classified them retrospectively into responders and non-responders using clinical criteria. Proton magnetic resonance spectroscopy and T-weighted structural MRI were acquired pre- and post-treatment to quantify striatal glutamate levels and several measures of subcortical brain structure.
Results: Patients were classified as 29 responders and 19 non-responders. Striatal glutamate was higher in the non-responders than responders both pre- and post-treatment (F = 7.15, p = .01). Volumetric measures showed a significant group x time interaction (t = 5.163, <1%FDR), and group x time x glutamate interaction (t = 4.23, <15%FDR) were seen in several brain regions. Striatal volumes increased at trend level with treatment in both groups, and a positive association of striatal volumes with glutamate levels was seen in the non-responders.
Conclusions: Combining anatomic measures with glutamate levels offers the potential to enhance classification of responders and non-responders to antipsychotic medications as well as to provide mechanistic understanding of the interplay between neuroanatomical and neurochemical changes induced by these medications. Ethical statement The study was approved by the Ethics and Scientific committees of the Instituto Nacional de Neurología y Neurocirugía in Mexico City. All participants over 18 years fully understood and signed the informed consent; in case the patient was under 18 years, informed consent was obtained from both parents. Participants did not receive a stipend.
Smucny J, Carter C, Maddock R Biol Psychiatry Cogn Neurosci Neuroimaging. 2023; 9(2):137-145.
PMID: 37925074 PMC: 11192527. DOI: 10.1016/j.bpsc.2023.10.008.
Santa C, Rodrigues D, Coelho J, Anjo S, Mendes V, Bessa-Neto D Transl Psychiatry. 2023; 13(1):312.
PMID: 37803004 PMC: 10558446. DOI: 10.1038/s41398-023-02609-w.
Fan L, Liang L, Wang Y, Ma X, Yuan L, Ouyang L Neuropsychopharmacology. 2023; 49(5):845-853.
PMID: 37752221 PMC: 10948866. DOI: 10.1038/s41386-023-01741-x.
Illness Phase as a Key Assessment and Intervention Window for Psychosis.
Kohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C Biol Psychiatry Glob Open Sci. 2023; 3(3):340-350.
PMID: 37519466 PMC: 10382701. DOI: 10.1016/j.bpsgos.2022.05.009.
Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis.
Merritt K, McCutcheon R, Aleman A, Ashley S, Beck K, Block W Mol Psychiatry. 2023; 28(5):2039-2048.
PMID: 36806762 PMC: 10575771. DOI: 10.1038/s41380-023-01991-7.